Dementia
Rare disease
No
- Definition
- Loss of intellectual abilities interfering with an individual's social and occupational functions. Causes include Alzheimer's disease, brain injuries, brain tumors, and vascular disorders.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Dementia
- dementia
- dementia
- dementia (disease)
- Severity
- Severe
- MONDO ID
- MONDO:0001627
- Parent condition
- MONDO:0002039
Related records
Broader conditions (5)
- Cognitive disorder
- Disease
- Disease by developmental or physiological process
- Human disease
- Psychiatric disorder
Narrower conditions (159)
- Aceruloplasminemia
- Adrenoleukodystrophy
- Adrenomyeloneuropathy
- AIDS dementia complex
- Alzheimer disease
- Alzheimer disease 10
- Alzheimer disease 11
- Alzheimer disease 12
- Alzheimer disease 13
- Alzheimer disease 14
- Alzheimer disease 16
- Alzheimer disease 17
- Alzheimer disease 18
- Alzheimer disease 19
- Alzheimer disease 2
- Alzheimer disease 3
- Alzheimer disease 4
- Alzheimer disease 5
- Alzheimer disease 6
- Alzheimer disease 7
Trials (2,307)
- "Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia Program"
- "Living Together With Dementia"_Creation and Validation of a Training Program for Family Caregivers of People With Dementia to Live at Home
- [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
- 10-Year Survival After Acute Hip Fracture in Patients With Preclinical/Clinical Alzheimer Pathology
- 100-Year Human Aging Study
- 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes
- 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
- 3D Team Care for Cognitively Vulnerable Older Adults
- 5-Cog 2.0: A Pragmatic Clinical Trial
- 5-Cog Battery for Detecting Cognitive Impairment and Dementia
- A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
- A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
- A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
- A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
- A Behavioural Sleep Intervention for People With Mild Cognitive Impairment and Mild Dementia
- A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
- A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
- A Care Empowerment Program Using Virtual Reality for Family Caregivers of People With Dementia
- A Clinical Decision Support Tool for Assessing the Ability to Decide on Returning Home in Elderly Patients with Cognitive Impairments
- A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
Approved drugs (15)
- Aducanumab
- Benzgalantamine gluconate
- Donanemab
- Donepezil
- Donepezil hydrochloride
- Galantamine
- Galantamine hydrobromide
- Ginkgo
- Ioflupane I 123
- Lecanemab
- Memantine
- Memantine hydrochloride
- Rivastigmine
- Rivastigmine tartrate
- Tacrine
Drugs in development (129)
- Acamprosate Phase 3
- Agomelatine Phase 3
- Alprazolam Phase 3
- Altropane I-123 Phase 3
- Ambroxol Phase 2
- Amisulpride Phase 3
- Amitriptyline Phase 3
- Aripiprazole Phase 3
- Benperidol Phase 3
- Biperiden Phase 3
- Bosutinib Phase 1
- Bromazepam Phase 3
- Bromperidol Phase 3
- Brotizolam Phase 3
- Bupropion Phase 3
- Buspirone Phase 3
- Cannabinol Phase 2
- Carbamazepine Phase 3
- Chloral hydrate Phase 3
- Chlorprothixene Phase 3
Other linked drugs (6)
- BIIB-080
- Buntanetap
- Cyclandelate
- Flortaucipir F 18
- Indeloxazine
- Oxiracetam